Dexibuprofen biodegradable nanoparticles: one step closer towards a better ocular interaction study

dc.contributor.author
Sánchez-López, E. (Elena)
dc.contributor.author
Esteruelas Navarro, Gerard
dc.contributor.author
Ortiz Rodrigo, Alba
dc.contributor.author
Espina García, Marta
dc.contributor.author
Prat Aixelà, Josefa
dc.contributor.author
Muñoz Juncosa, Montserrat
dc.contributor.author
Cano Fernández, Amanda
dc.contributor.author
Calpena Campmany, Ana Cristina
dc.contributor.author
Ettcheto Arriola, Miren
dc.contributor.author
Camins Espuny, Antoni
dc.contributor.author
Alsafi, Zaid
dc.contributor.author
Souto, Eliana B.
dc.contributor.author
García López, María Luisa
dc.contributor.author
Pujol Cubells, Montserrat
dc.date.issued
2020-06-18T09:01:41Z
dc.date.issued
2020-06-18T09:01:41Z
dc.date.issued
2020-04-10
dc.date.issued
2020-06-18T09:01:41Z
dc.identifier
2079-4991
dc.identifier
https://hdl.handle.net/2445/166211
dc.identifier
702031
dc.identifier
32290252
dc.description.abstract
Ocular inflammation is one of the most prevalent diseases in ophthalmology, which can affect various parts of the eye or the surrounding tissues. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, are commonly used to treat ocular inflammation in the form of eye-drops. However, their bioavailability in ocular tissues is very low (less than 5%). Therefore, drug delivery systems such as biodegradable polymeric PLGA nanoparticles constitute a suitable alternative to topical eye administration, as they can improve ocular bioavailability and simultaneously reduce drug induced side effects. Moreover, their prolonged drug release can enhance patient treatment adherence as they require fewer administrations. Therefore, several formulations of PLGA based nanoparticles encapsulating dexibuprofen (active enantiomer of Ibuprofen) were prepared using the solvent displacement method employing different surfactants. The formulations have been characterized and their interactions with a customized lipid corneal membrane model were studied. Ex vivo permeation through ocular tissues and in vivo anti-inflammatory efficacy have also been studied.
dc.format
24 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/nano10040720
dc.relation
Nanomaterials, 2020, vol. 10, num. 4, art. 720
dc.relation
https://doi.org/10.3390/nano10040720
dc.rights
cc-by (c) Sánchez-López E. et al., 2020
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject
Sistemes d'alliberament de medicaments
dc.subject
Agents antiinflamatoris
dc.subject
Oftalmopaties
dc.subject
Drug delivery systems
dc.subject
Antiinflammatory agents
dc.subject
Ophthalmopathies
dc.title
Dexibuprofen biodegradable nanoparticles: one step closer towards a better ocular interaction study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.